ALLAKOS INC (ALLK)
US01671P1003 - Common Stock
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was...
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
ALLK stock results show that Allakos beat analyst estimates for earnings per share the second quarter of 2024.
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ:ALLK) just reported results for the second quarter of 2024.Alla...
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects...
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a...
ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
ALLK stock results show that Allakos met analyst estimates for earnings per share the first quarter of 2024.
ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ:ALLK) just reported results for the first quarter of 2024.Allak...
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out this morning as we dive into all of the biggest news moving shares on Friday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
ALLK stock results show that Allakos missed analyst estimates for earnings per share the fourth quarter of 2023.
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ:ALLK) just reported results for the fourth quarter of 2023.Alla...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
Commit To Buy Allakos At $1, Earn 17.9% Annualized Using Options
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast...
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK). Such investors are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK). Such investors are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK). Such investors are...
Allakos stock falls as analysts downgrade (NASDAQ:ALLK)
Allakos (ALLK) stock faced downgrades as Wall Street reacted to Phase 2 setbacks for its lead asset lirentelimab that led to massive layoffs. Read more here.